comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 17:02:35 - browse：47

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Addiction experts warn against a second 'war on drugs'

knowledge

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

Inequities make cancer less preventable for women: report

Wearables generate powerful data but its not useful to doctors, yet

Case highlights the risks of experimental stem cell therapy

Readers respond to H5N1 and livestock movements, and more

Ionis has late

Wikipedia

comprehensive

focus

Duchenne breakthrough therapy leaves behind pioneering families

Medicaid, Medicare dual

Psychedelics group wrestles with new pharma identity

Addiction experts warn against a second 'war on drugs'

Dobbs anniversary: the lost opportunity of abortion as health care

Did you have Obamacare on your GOP debate bingo card?

The high cost of giving birth even with insurance

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

As demand for Covid shots wanes, Moderna seeks its next success

When prostate cancer spreads, where it goes matters

focus

Address the ethical violations that led to 'Three Identical Strangers'

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Sudafed saga points to U.S. issues with evaluating older drugs

WHO recommends dropping component of many flu vaccines

Did you have Obamacare on your GOP debate bingo card?

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

entertainment

hotspot

knowledge

entertainment